In this article by Pharma Focus, Dr. Andrew Lewis, the Chief Scientific Officer at Quotient Sciences discusses the efficiency of oral peptides and their attractiveness as a drug candidate.
"Continued advancements in drug delivery technologies will be crucial for improving oral peptides’ bioavailability, convenience and efficacy"
The increased availability of oral peptides promising development opens new horizons in GLP-1 treatment for not only obesity and diabetes but to related conditions, such as chronic kidney disease and end-stage renal disease.
Continue reading the article on Pharma Focus
Credit:
Pharmafocus, Volume 26 Issue 7, September 2024, pages 22-23. © Samedan Ltd